GeNeuro SA
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical tr…
Biotechnology
CH, Plan-les-Ouates [HQ]
Cash Flow Statements
11 Records · Starting from 2013In Million EUR. Margins, Growth Rates In %
| Metric | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||
| Operating Cash Flow (OCF) | -3.00 | 2.00 | - - | - - | - - | - - | -10.00 | -7.00 | -6.00 | -13.00 | -10.00 | |
| Operating Cash (Net) | -3.00 | 2.00 | - - | - - | - - | - - | -10.00 | -7.00 | -6.00 | -13.00 | -10.00 | |
| Accounts Receivable | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Accounts Payable | - - | - - | - - | 1.00 | - - | 1.00 | -4.00 | - - | - - | - - | - - | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Change | - - | 1.00 | - - | - - | -2.00 | -10.00 | -1.00 | - - | - - | -1.00 | 3.00 | |
| Other WC | - - | 1.00 | - - | -1.00 | -2.00 | -12.00 | 2.00 | - - | - - | -1.00 | 3.00 | |
| Investing Activities | ||||||||||||
| Used Cash (Net) | -1.00 | -2.00 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Capital Expenditure | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Purchases of Investments | -3.00 | -4.00 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Sale/Maturity of Investment | 1.00 | 2.00 | 4.00 | 1.00 | - - | - - | - - | - - | - - | - - | - - | |
| Property, Plant, Equipment (P&PE) | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Acquisitions (Net) | - - | - - | -3.00 | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Investing Activities | - - | - - | -3.00 | - - | - - | - - | - - | - - | - - | - - | - - | |
| Financing Activities | ||||||||||||
| Used Cash (Net) | -2.00 | -1.00 | - - | - - | - - | - - | -7.00 | -8.00 | -5.00 | -13.00 | -6.00 | |
| Debt Repayment | - - | - - | - - | - - | - - | - - | -7.00 | - - | - - | -6.00 | -6.00 | |
| Dividends Paid | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Common Stock
|
2 | 2 | - - | 34 | - - | - - | - - | 8 | - - | - - | - - | |
| Issued | 2.00 | 2.00 | - - | 32.00 | - - | - - | - - | 8.00 | 5.00 | 7.00 | - - | |
| Repurchased | - - | - - | - - | -2.00 | - - | - - | - - | - - | - - | - - | - - | |
| Other Financing Activities | - - | - - | - - | -30.00 | - - | - - | 14.00 | - - | - - | 12.00 | - - | |
| Cash Balances | ||||||||||||
| Begin of Period | 3.00 | 1.00 | - - | - - | - - | - - | 8.00 | 5.00 | 6.00 | 5.00 | 5.00 | |
| End of Period | 1.00 | 3.00 | - - | - - | - - | - - | 5.00 | 6.00 | 5.00 | 5.00 | 1.00 | |
| Change | -2.00 | 2.00 | - - | - - | - - | - - | -3.00 | - - | -1.00 | - - | -3.00 | |
| Non-Cash Balances | ||||||||||||
| Depreciation and Amortization | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Stock Based Compensation | - - | - - | - - | - - | - - | - - | - - | 1.00 | - - | - - | - - | |
| Other | - - | - - | - - | - - | 2.00 | - - | 5.00 | 2.00 | - - | 1.00 | - - | |
| Highlighted metrics | ||||||||||||
| Free Cash Flow (FCF) | -3.00 | 2.00 | - - | - - | - - | - - | -10.00 | -7.00 | -6.00 | -13.00 | -10.00 | |
| Cash Conversion Cycle (CCC) | - - | - - | 99,161.00 | 36,143.00 | 26,756.00 | 125,377.00 | - - | - - | - - | - - | - - | |
| Invested Capital | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
||||||||||||
| Forex Effect on Cash | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - |